Lengthening the lifespan of mighty humans with a tiny probiotic Bifidobacterium lactis (BL) HY8101: Probiotic Bifidobacterium lactis (BL) HY8101 may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others longevity-promoting genes, 7/November/2018, 11.26 pm

 What they say: Introduction:  A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston, USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of […]

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as IGFBP3, PIAS3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 6/November/2018,11.28 pm

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows that “Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1.” This study was published, in the 30 August […]

Probiotic-based therapy for cancer metastasis: Probiotic Lactobacillus Rhamnosus inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via upregulation of its target gene, 6/November/2017, 11.06 pm

Introduction: What they say: A study from Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, USA; Johns Hopkins Physical Sciences-Oncology Center, The Johns Hopkins University, Baltimore, Maryland 21218, USA; and Department of Oncology and Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA shows that “Synergistic […]

The known anti-hypertensive agent Candesartan may safeguard your heart against cardiac dysfunction:  Candesartan,, an angiotensin II receptor blocker, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 6/November/2018, 10.40 pm

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China; and Department of Pathology and Laboratory Medicine, University […]

Probiotic-based anti-cancer therapy for CyclinD3-CDK6 overexpressing cancers:Probiotic Lactobacillus Rhamnosus inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down-regulation of its target gene, 6/November/2018,10.27 pm

Introduction: What they say A study from Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; and Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA shows that “The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.” This research paper was published, in the 15 June 2017 issue of the journal “Nature” […]

Molecular therapy for Myocardial Infarction: Candesartan, an angiotensin II receptor blocker, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 6/November/2018, 10.16  pm

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler, Boon, and others. What we say:  On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: Candesartan, an angiotensin […]